Cargando…

Summary data of potency and parameter information from semi-mechanistic PKPD modeling of prolactin release following administration of the dopamine D(2) receptor antagonists risperidone, paliperidone and remoxipride in rats

We provide the reader with relevant data related to our recently published paper, comparing two mathematical models to describe prolactin turnover in rats following one or two doses of the dopamine D(2) receptor antagonists risperidone, paliperidone and remoxipride, “A comparison of two semi-mechani...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taneja, Amit, Vermeulen, An, Huntjens, Dymphy R.H., Danhof, Meindert, De Lange, Elizabeth C.M., Proost, Johannes H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Data Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007417/ https://www.ncbi.nlm.nih.gov/pubmed/27617278 http://dx.doi.org/10.1016/j.dib.2016.07.060

Ejemplares similares

Modeling of prolactin response following dopamine D(2) receptor antagonists in rats: can it be translated to clinical dosing?
por: Taneja, Amit, et al.
Publicado: (2017)

Pharmacokinetic-Pharmacodynamic Modeling of the D(2) and 5-HT(2A) Receptor Occupancy of Risperidone and Paliperidone in Rats
por: Kozielska, Magdalena, et al.
Publicado: (2012)

Audit on prolactin monitoring for patients on oral risperidone, intramuscular risperidone, and intramuscular paliperidone
por: Bader, Mohamed
Publicado: (2021)

Comparative Pharmacology of Risperidone and Paliperidone
por: Corena-McLeod, Maria
Publicado: (2015)

Determination of Plasma Concentration Reference Ranges for Risperidone and Paliperidone
por: Korell, J, et al.
Publicado: (2017)

The effects of concurrent oral paliperidone or risperidone use with paliperidone long-acting injection
por: Stump, Trevor A., et al.
Publicado: (2021)

Evidence based administration of risperidone and paliperidone for the treating conduct disorder
por: Ghanizadeh, Ahmad
Publicado: (2013)

Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling of the Dopamine D(2) Receptor Occupancy of Olanzapine in Rats
por: Johnson, Martin, et al.
Publicado: (2011)

Aripiprazole combination for reversal of paliperidone-induced increase in prolactin level
por: Zhi, Pu, et al.
Publicado: (2018)

Erratum to: Translational Modeling in Schizophrenia: Predicting Human Dopamine D(2) Receptor Occupancy
por: Johnson, Martin, et al.
Publicado: (2016)

In vitro and in silico analysis of the effects of D (2) receptor antagonist target binding kinetics on the cellular response to fluctuating dopamine concentrations
por: de Witte, Wilhelmus E A, et al.
Publicado: (2018)

Predicting Drug Concentration‐Time Profiles in Multiple CNS Compartments Using a Comprehensive Physiologically‐Based Pharmacokinetic Model
por: Yamamoto, Yumi, et al.
Publicado: (2017)

Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate
por: Patel, Charmi, et al.
Publicado: (2019)

Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
por: Alphs, Larry, et al.
Publicado: (2013)

Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis
por: Turkoz, Ibrahim, et al.
Publicado: (2011)

S56. SWITCHING FROM RISPERIDONE TO PALIPERIDONE PALMITATE IN SCHIZOPHRENIA: CHANGES IN COGNITIVE FUNCTION
por: Tost Bonet, Meritxell, et al.
Publicado: (2020)

Dosing strategies for switching from oral risperidone to paliperidone palmitate: Effects on clinical outcomes
por: Hsia, Stephanie L., et al.
Publicado: (2018)

PM409. Paliperidone Palmitate 3-Monthly vs. 1-Monthly Injectable in Schizophrenia Patients with or without Prior Exposure to Oral Risperidone or Paliperidone
por: Mathews, Maju, et al.
Publicado: (2016)

Effects of Risperidone and Paliperidone on Brain-Derived Neurotrophic Factor and N400 in First-Episode Schizophrenia
por: Wu, Rong-Qin, et al.
Publicado: (2018)

Tachycardia during Treatment with Risperidone and Paliperidone Palmitate in a Patient without Previous Cardiovascular Disease
por: Orlins, Zachary, et al.
Publicado: (2021)

PKPD modeling of acquired resistance to anti-cancer drug treatment
por: Eigenmann, Miro J., et al.
Publicado: (2017)

Considerations for Intravenous Anesthesia Dose in Obese Children: Understanding PKPD
por: Morse, James Denzil, et al.
Publicado: (2023)

PhysiPKPD: A pharmacokinetics and pharmacodynamics module for PhysiCell
por: Bergman, Daniel, et al.
Publicado: (2022)

A comparison of the metabolic side-effects of the second-generation antipsychotic drugs risperidone and paliperidone in animal models
por: Boyda, Heidi N., et al.
Publicado: (2021)

Prolactin variations during risperidone therapy in a sample of drug-naive children and adolescents
por: Margari, Lucia, et al.
Publicado: (2015)

Comparison of risperidone, olanzapine and quetiapine: effects on body weight, serum blood glucose and prolactin
por: Chaudhry, Haroon Rashid, et al.
Publicado: (2008)

Healthcare Resource Utilization and Costs Among Patients With Schizophrenia Switching From Oral Risperidone/Paliperidone to Once-Monthly Paliperidone Palmitate: A Veterans Health Administration Claims Analysis
por: Patel, Charmi, et al.
Publicado: (2020)

Comparison of Capillary and Venous Plasma Drug Concentrations After Repeated Administration of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole
por: Remmerie, Bart, et al.
Publicado: (2016)

Randomized Controlled Trial of Paliperidone Extended Release Versus Risperidone for the Treatment of Methamphetamine-Associated Psychosis in Chinese Patients
por: Wang, Gang, et al.
Publicado: (2020)

Assessment of risk factors of treatment discontinuation among patients on paliperidone palmitate and risperidone microspheres in France, Germany and Belgium
por: Cai, Rui, et al.
Publicado: (2022)

Paliperidone Palmitate versus Risperidone Long-Acting Injectable in Patients with Schizophrenia: A Meta-Analysis of Efficacy and Safety
por: Zhao, Mingjun, et al.
Publicado: (2023)

PKPD Modeling of the Inoculum Effect of Acinetobacter baumannii on Polymyxin B in vivo
por: Chauzy, Alexia, et al.
Publicado: (2022)

A Generic Multi-Compartmental CNS Distribution Model Structure for 9 Drugs Allows Prediction of Human Brain Target Site Concentrations
por: Yamamoto, Yumi, et al.
Publicado: (2016)

Comparison of Capillary and Venous Drug Concentrations After Administration of a Single Dose of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole
por: Remmerie, Bart, et al.
Publicado: (2016)

Maintenance dose conversion between oral risperidone and paliperidone palmitate 1 month: Practical guidance based on pharmacokinetic simulations
por: Russu, Alberto, et al.
Publicado: (2018)

Simultaneous pharmacokinetic/pharmacodynamic (PKPD) assessment of ampicillin and gentamicin in the treatment of neonatal sepsis
por: Gastine, Silke, et al.
Publicado: (2021)

Kinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models
por: Danhof, Meindert
Publicado: (2015)

Pharmacogenomics Factors Influencing the Effect of Risperidone on Prolactin Levels in Thai Pediatric Patients With Autism Spectrum Disorder
por: Hongkaew, Yaowaluck, et al.
Publicado: (2021)

Are the Long-Acting Intramuscular Formulations of Risperidone or Paliperidone Palmitate Associated with Post-Injection Delirium/Sedation Syndrome? An Assessment of Safety Databases
por: Alphs, Larry, et al.
Publicado: (2011)

Physiologically‐based pharmacokinetic model to investigate the effect of pregnancy on risperidone and paliperidone pharmacokinetics: Application to a pregnant woman and her neonate
por: Mahdy, Walaa Y. B., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_narvj4b3bs0p27d7ob5reoe4ng